Navigation Links
Risk Of Soft Tissue Sarcomas In Hereditary Retinoblastoma Survivors

A study by Ruth A. Kleinerman and his colleagues quantifies the risk of hereditary retinoblastoma survivors developing specific subtypes of soft tissue sarcomas and finds that// this risk persists for decades after the original retinoblastoma diagnosis.

The findings published in the January 3 issue of the Journal of the National Cancer Institute emphasizes the importance of regular medical surveillance for these patients, the authors say.

Retinoblastoma is a rare cancer of the retina that primarily affects children and is most often diagnosed before age 1. The disease can often be cured; 97 percent of retinoblastoma patients survive 5 years after diagnosis.

However, patients with hereditary retinoblastoma are at a high risk of developing another cancer, including soft tissue sarcomas. The increased risk of soft tissue sarcomas is attributed both to the mutation in the RB-1 gene that causes retinoblastoma and to the radiation treatment that most retinoblastoma patients received when treated decades ago. Radiation is used less frequently today because of the risk of second cancers.

The researchers at the National Cancer Institute in Bethesda, Md., studied a group of 963 1-year hereditary retinoblastoma survivors to better understand the risks for specific subtypes of soft tissue sarcomas. The patients were diagnosed between 1914 and 1984 at medical centers in New York and Boston and were followed for an average of 25.2 years. More than half of the patients were younger than 1-year-old when diagnosed, and most (88.2 percent) of the patients were treated with radiation.

A total of 69 soft tissue sarcomas were diagnosed in 68 hereditary retinoblastoma patients. The most common subtype was leiomyosarcoma, a cancer of smooth muscle cells that was diagnosed in 23 of the patients. Other frequently diagnosed sarcomas were fibrosarcoma (13 patients), malignant fibrous histiocytoma (12), rhabdomyosarcoma (8), and liposarcoma ( 3). The authors calculated that there was a 184-fold increase in soft-tissue sarcomas among hereditary retinoblastoma survivors compared with the general population and a 390-fold increase in cases of leiomyosarcomas.

Only 20 percent of the soft tissue sarcomas were diagnosed within 10 years of the retinoblastoma diagnosis; 45 percent of the sarcomas arose 30 or more years after diagnosis. In addition, 18 of the 23 (78 percent) leiomyosarcomas were diagnosed 30 or more years after the diagnosis of retinoblastoma. Almost all sarcomas were diagnosed in retinoblastoma survivors who had been treated with radiation. However, 18 of the 69 sarcomas developed outside the original radiation treatment field, and leiomyosarcoma was diagnosed more often outside the radiation field than in it.

The authors note that some of their calculations are based on few cases of these rare cancers. In addition, classification schemes for some sarcomas changed over the study period, so some cancer subtypes may have been classified differently depending on the year they were diagnosed.

"Given the excellent survival of retinoblastoma patients, it is important that survivors continue to undergo regular medical surveillance for sarcomas in their adult years," the authors write.

In an editorial, Anna Meadows, M.D., of The Children's Hospital of Philadelphia, highlights the advances in treatment for retinoblastoma in the last several decades, and she notes that some of these findings may be applicable only to patients who received treatments that are no longer used. "Improved treatment can be expected to reduce the incidence of soft tissue (and bone) sarcomas associated with radiation," Meadows writes.

"The importance of this [new] report lies in its emphasis on leiomyosarcoma, a tumor that occurs in RB-1 gene carriers whether or not they were treated with radiation and that can be expected to continue to occur in older survivors, who will require more careful follow-up."

Source-Eurekalert
SRI
'"/>




Related medicine news :

1. Free Tissue Transfer Effective in Treating Massive Skin Cancers
2. Tissue Transfer for Skin Cancer
3. Tissue Transfer For Treatment Of Massive Skin Cancers
4. Loss Of Brain Tissue Linked To Obesity
5. Low Cost Tissue Culture Vaccine For Encephalitis
6. Adult Stem Cells From Fat Tissues For Healing
7. Stem cell therapy for developing new trachea using Tissue engineering
8. A Novel Method For Measuring Interstitial Fluid Pressure In Cancer Tissues
9. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
10. Bisphenol A In Food Containers Has Adverse Effect On Brain Tissue
11. Lack Of Estrogen In Brain Tissue Of Women Can Lead To Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: